AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510-2483, USA.
Curr Infect Dis Rep. 2007 May;9(3):252-61. doi: 10.1007/s11908-007-0039-7.
The worldwide epidemics of tuberculosis (TB) and HIV/AIDS have been joined by an insidiously developing third epidemic of TB drug resistance. Fueled by the disruption of TB control programs and the explosive growth of HIV/AIDS, the presence of TB drug resistance, particularly multiple drug resistance, is worldwide and threatens the gains made in the past decades in the treatment of both TB and HIV. Although treatment success is possible, the diagnosis and treatment of drug-resistant TB is difficult. Advances in TB diagnosis and treatment have been minimal in the past 40 years, and there is an urgent need for wider distribution of available diagnostic technology and for the development and testing of newer rapid molecular diagnostic techniques and therapeutic agents. This review discusses current information about the distribution of multiple drug-resistant and newer extensively drug-resistant TB as well as available diagnostic and therapeutic strategies with an emphasis on the relationship between TB drug resistance and HIV/AIDS.
结核病(TB)和艾滋病(HIV/AIDS)在全球范围内的流行,又出现了一种潜伏性发展的第三种结核病耐药性流行。由于结核病控制项目的中断和艾滋病毒/艾滋病的爆发式增长,结核病耐药性的存在,特别是耐多药结核病的存在,是全球性的,并威胁到过去几十年在结核病和艾滋病治疗方面取得的成果。尽管有可能治愈,但耐药结核病的诊断和治疗是困难的。在过去的 40 年中,结核病的诊断和治疗进展甚微,迫切需要更广泛地分发现有的诊断技术,并开发和测试新的快速分子诊断技术和治疗剂。这篇综述讨论了耐多药和新型广泛耐药结核病的分布情况以及现有的诊断和治疗策略,重点是结核病耐药性与艾滋病毒/艾滋病之间的关系。